291 related articles for article (PubMed ID: 32998859)
1. Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva.
Bartoletti M; Mazzeo R; De Scordilli M; Del Fabro A; Vitale MG; Bortot L; Nicoloso MS; Corsetti S; Bonotto M; Scalone S; Giorda G; Sorio R; Andreetta C; Meacci ML; De Vivo R; Fasola G; Sopracordevole F; Puglisi F
Int J Gynecol Cancer; 2020 Nov; 30(11):1672-1677. PubMed ID: 32998859
[TBL] [Abstract][Full Text] [Related]
2. Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
Watanabe S; Takeda M; Takahama T; Iwasa T; Tsurutani J; Tanizaki J; Shimizu T; Sakai K; Wada Y; Isogai N; Nishio K; Nakagawa K
Invest New Drugs; 2016 Jun; 34(3):394-6. PubMed ID: 26856856
[TBL] [Abstract][Full Text] [Related]
3. Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget's disease: Four cases and a review.
Sekiguchi N; Kubota S; Noguchi T; Fukushima T; Kobayashi T; Kanda S; Koizumi T; Miyake T; Shirai T; Okuyama R
J Dermatol; 2020 Nov; 47(11):1276-1279. PubMed ID: 32706146
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06.
Sohn BS; Kim J; Kim M; Hong JY; Lee J; Park SE; Kim H; Lee HJ; Kang EJ; Lee SI; Lee IH; Huh SJ; Jo J; Kim HY
Cancer Med; 2023 Jul; 12(14):15159-15175. PubMed ID: 37264748
[TBL] [Abstract][Full Text] [Related]
6. Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy.
Takahagi S; Noda H; Kamegashira A; Madokoro N; Hori I; Shindo H; Mihara S; Hide M
J Dermatol; 2009 Aug; 36(8):457-61. PubMed ID: 19691751
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102).
Nishikawa K; Takahashi T; Takaishi H; Miki A; Noshiro H; Yoshikawa T; Nishida Y; Iwasa S; Miwa H; Masuishi T; Boku N; Yamada Y; Kodera Y; Yoshida K; Morita S; Sakamoto J; Saji S; Kitagawa Y
Int J Cancer; 2017 Jan; 140(1):188-196. PubMed ID: 27521503
[TBL] [Abstract][Full Text] [Related]
8. HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review.
Karam A; Berek JS; Stenson A; Rao J; Dorigo O
Gynecol Oncol; 2008 Dec; 111(3):568-71. PubMed ID: 18252264
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
10. Complete but transient clinical remission of vulvar Paget's disease with paclitaxel and trastuzumab.
Isnard C; Plantier F; Thériaut M; Avril MF; Moyal-Barracco M
Ann Dermatol Venereol; 2021 Mar; 148(1):47-48. PubMed ID: 33422298
[No Abstract] [Full Text] [Related]
11. Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease.
Hirai I; Tanese K; Nakamura Y; Ishii M; Kawakami Y; Funakoshi T
Oncologist; 2019 Jun; 24(6):e394-e396. PubMed ID: 30846514
[TBL] [Abstract][Full Text] [Related]
12. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
13. Low-dose mitomycin C, etoposide, and cisplatin for invasive vulvar Paget's disease.
Watanabe Y; Hoshiai H; Ueda H; Nakai H; Obata K; Noda K
Int J Gynecol Cancer; 2002; 12(3):304-7. PubMed ID: 12060453
[TBL] [Abstract][Full Text] [Related]
14. Imiquimod in vulvar Paget's disease: a case report.
Geisler JP; Manahan KJ
J Reprod Med; 2008 Oct; 53(10):811-2. PubMed ID: 19004411
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
16. Treatment of a vulvar Paget's disease by photodynamic therapy with a new light emitting fabric based device.
Vicentini C; Carpentier O; Lecomte F; Thecua E; Mortier L; Mordon SR
Lasers Surg Med; 2017 Feb; 49(2):177-180. PubMed ID: 28103628
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerance of photodynamic therapy for vulvar Paget's disease: a multicentric retrospective study.
Rioli DI; Samimi M; Beneton N; Hainaut E; Martin L; Misery L; Quereux G
Eur J Dermatol; 2018 Jun; 28(3):351-355. PubMed ID: 29976540
[TBL] [Abstract][Full Text] [Related]
19. Metastatic Extramammary Paget's Disease with near-complete response to trastuzumab and paclitaxel therapy.
Dao A; Chung AD; Gray G
Arch Gynecol Obstet; 2024 Jul; 310(1):595-597. PubMed ID: 38494513
[No Abstract] [Full Text] [Related]
20. Successful and long-term response to trastuzumab plus paclitaxel combination therapy in human epidermal growth factor receptor 2-positive extramammary Paget's disease: A case report and review of the literature.
Ichiyama T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Mamiya K; Koizumi T; Hama Y
Mol Clin Oncol; 2017 Nov; 7(5):763-766. PubMed ID: 29181166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
